Trials
1 active
3 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Allocetra is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, induced to an apoptotic stable state.”In the company’s words, NCT07580716 on ClinicalTrials.gov
- Tested for
- Primary Knee Osteoarthritis
- Main trialPhase 2
- “This is a multicenter, randomized, double-blind, placebo-controlled, Phase IIb study to evaluate intra-articular (IA) injections of Allocetra in participants with moderate-to-severe age related symptomatic primary knee osteoarthritis (OA).”In the company’s words, NCT07580716 on ClinicalTrials.gov
Other drugs for Primary Knee Osteoarthritis
- JointstemR-Bio · Phase 3
- DiacereinTRB Chemedica · Phase 3
- Mesenchymal Stem CellsWuxi Cellular Biopharmaceutical Group Ltd. · Phase 3
- PTP-01Doron Therapeutics Inc. · Phase 3
- Sodium hyaluronateIBSA Institut Biochimique SA · Phase 3
- Pentosan Polysulfate SodiumParadigm Biopharmaceuticals Ltd. · Phase 3
Coming up1
- Feb 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Feb 2027 | Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis | |
| Phase 1/2Completed | 15 Mar 2026 | Study of Intra-articular Allocetra in Knee Osteoarthritis | |
| Phase 1Terminated | 20 Oct 2025 | Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026